PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model

Nature Communications

Volumn 5, Issue , 2014, Pages

  Low, Pei Ching ^a   Manzanero, Silvia ^a   Mohannak, Nika ^a   Narayana, Vinod K ^a   Nguyen, Tam H ^a   Kvaskoff, David ^a   Brennan, Faith H ^a   Ruitenberg, Marc J ^a   Gelderblom, Mathias ^b   Magnus, Tim ^b   Kim, Hyun Ah ^c   Broughton, Brad R S ^c   Sobey, Christopher G ^c   Vanhaesebroeck, Bart ^d   Stow, Jennifer L ^a   Arumugam, Thiruma V ^a   Meunier, Frédéric A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSE OF DEATH; CELLS AND CELL COMPONENTS; DAMAGE; GENE; GENE EXPRESSION; INHIBITION; NUMERICAL MODEL; RODENT; SECRETION; TUMOR;

MUS;

PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CD PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; ENZYMOLOGY; INFLAMMATION; MALE; METABOLISM; MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84931272198     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4450     Document Type: Article

References (52)

1. Falluji, N., Abou-Chebl, A., Castro, C.E.& Mukherjee, D.Reperfusion strategies for acute ischemic stroke.Angiology 63, 289-296 (2012).
2. Esposito, E.& Cuzzocrea, S.TNFa as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma.Curr.Med.Chem.16, 3152 3167 (2009).
3. Botchkina, G.I., Meistrell, 3rd M.E., Botchkina, I.L.& Tracey, K.J.Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia.Mol.Med.3, 765-781 (1997).
4. Zaremba, J.& Losy, J.Early TNFa levels correlate with ischaemic stroke severity.Acta.Neurol.Scand.104, 288-295 (2001).
5. Pan, W.& Kastin, A.J.Tumor necrosis factor and stroke: role of the bloodbrain barrier.Prog.Neurobiol.83, 363-374 (2007).
6. Hallenbeck, J.M.The many faces of tumor necrosis factor in stroke.Nat.Med.8, 1363-1368 (2002).
7. Sumbria, R.K., Boado, R.J.& Pardridge, W.M.Brain protection from stroke with intravenous TNFa decoy receptor-Trojan horse fusion protein.J.Cereb.Blood Flow Metab.32, 1933-1938 (2012).
8. Eltzschig, H.K.& Eckle, T.Ischemia and reperfusion-from mechanism to translation.Nat.Med.17, 1391-1401 (2011).
9. Moskowitz, M.A., Lo, E.H.& Iadecola, C.The science of stroke: mechanisms in search of treatments.Neuron 67, 181-198 (2010).
10. Liebeskind, D.S.Reperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics.Curr.Opin.Neurol.23, 36-45 (2010).
11. Barone, F.C.et al.Tumor necrosis factor-alpha.A mediator of focal ischemic brain injury.Stroke 28, 1233-1244 (1997).
12. Iadecola, C.& Anrather, J.The immunology of stroke: from mechanisms to translation.Nat.Med.17, 796-808 (2011).
13. Bruce, A.J.et al.Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors.Nat.Med.2, 788-794 (1996).
14. Seals, D.F.& Courtneidge, S.A.The ADAMs family of metalloproteases: multidomain proteins with multiple functions.Genes Dev.17, 7-30 (2003).
15. Puri, K.D.& Gold, M.R.Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.Front.Immunol.3, 256 (2012).
16. Furman, R.R.et al.Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.New Engl.J.Med.doi:10.1056/NEJMoa1315226 (2014).
17. Gopal, A.K.et al.PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma.New Engl.J.Med.doi:10.1056/NEJMoa1314583 (2014).
18. Low, P.C.et al.Phosphoinositide 3-kinase delta regulates membrane fission of Golgi carriers for selective cytokine secretion.J.Cell Biol.190, 1053-1065 (2010).
19. Lacy, P.& Stow, J.L.Cytokine release from innate immune cells: association with diverse membrane trafficking pathways.Blood 118, 9-18 (2011).
20. Ali, K.et al.Essential role for the p110d phosphoinositide 3-kinase in the allergic response.Nature 431, 1007-1011 (2004).
21. Kim, N.et al.The p110d catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion.Blood 110, 3202-3208 (2007).
22. Dil, N.& Marshall, A.J.Role of phosphoinositide 3-kinase p110d in TLR4-and TLR9-mediated B cell cytokine production and differentiation.Mol.Immunol.46, 1970-1978 (2009).
23. Hoellenriegel, J.et al.The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.Blood 118, 3603-3612 (2011).
24. Soond, D.R.et al.PI3K p110d regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.Blood 115, 2203-2213 (2010).
25. Sadhu, C., Dick, K., Tino, W.T.& Staunton, D.E.Selective role of PI3Kd in neutrophil inflammatory responses.Biochem.Biophys.Res.Commun.308, 764-769 (2003).
26. Nashed, B.F.et al.Role of the phosphoinositide 3-kinase p110d in generation of type 2 cytokine responses and allergic airway inflammation.Eur.J.Immunol.37, 416-424 (2007).
27. Doukas, J.et al.Phosphoinositide 3-kinase g/d inhibition limits infarct size after myocardial ischemia/reperfusion injury.Proc.Natl Acad.Sci.USA 103, 19866-19871 (2006).
28. Eickholt, B.J.et al.Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase.PLoS One 2, e869 (2007).
29. Woodruff, T.M.et al.Pathophysiology, treatment, and animal and cellular models of human ischemic stroke.Mol.Neurodegener.6, 11 (2011).
30. Okkenhaug, K.et al.Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.Science 297, 1031-1034 (2002).
31. Lannutti, B.J.et al.CAL-101, a p110d selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood 117, 591-594 (2011).
32. Murray, R.Z., Kay, J.G., Sangermani, D.G.& Stow, J.L.A role for the phagosome in cytokine secretion.Science 310, 1492-1495 (2005).
33. Gelderblom, M.et al.The flavonoid fisetin attenuates postischemic immune cell infiltration, activation and infarct size after transient cerebral middle artery occlusion in mice.J.Cereb.Blood Flow Metab.32, 835-843 (2012).
34. Arumugam, T.V.et al.Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death.Proc.Natl Acad.Sci.USA 104, 14104-14109 (2007).
35. Arumugam, T.V.et al.g-secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke.Nat.Med.12, 621-623 (2006)).
36. Dawson, D.A.& Hallenbeck, J.M.Acute focal ischemia-induced alterations in MAP2 immunostaining: description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury.J.Cereb.Blood Flow Metab.16, 170-174 (1996).
37. Costes, S.V.et al.Automatic and quantitative measurement of protein-protein colocalization in live cells.Biophys.J.86, 3993-4003 (2004).
38. Tomatis, V.M.et al.Myosin VI small insert isoform maintains exocytosis by tethering secretory granules to the cortical actin.J.Cell Biol.200, 301-320 (2013).
39. Liu, S., Levine, S.R.& Winn, H.R.Targeting ischemic penumbra: part I-from pathophysiology to therapeutic strategy.J.Exp.Stroke Transl.Med.3, 47-55 (2010).
40. Gelderblom, M.et al.Temporal and spatial dynamics of cerebral immune cell accumulation in stroke.Stroke 40, 1849-1857 (2009).
41. Lambertsen, K.L.et al.Microglia protect neurons against ischemia by synthesis of tumor necrosis factor.J.Neurosci.29, 1319-1330 (2009).
42. Stow, J.L.& Murray, R.Z.Intracellular trafficking and secretion of inflammatory cytokines.Cytokine Growth Factor Rev.24, 227-239 (2013).
43. McCoy, M.K.& Tansey, M.G.TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.J.Neuroinflammation 5, 45 (2008).
44. Gelderblom, M.et al.Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke.Blood 120, 3793-3802 (2012).
45. Prestigiacomo, C.J.et al.CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke.Stroke 30, 1110-1117 (1999).
46. Wang, P.Y., Kao, C.H., Mui, M.Y.& Wang, S.J.Leukocyte infiltration in acute hemispheric ischemic stroke.Stroke 24, 236-240 (1993).
47. Price, C.J.et al.Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study.Stroke 35, 1659-1664 (2004).
48. Puri, K.D.et al.Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue.Blood 103, 3448-3456 (2004).
49. Blomster, L.V.et al.Mobilisation of the splenic monocyte reservoir and peripheral CX(3)CR1 deficiency adversely affects recovery from spinal cord injury.Exp.Neurol.247, 226-240 (2013).
50. Jung, S.et al.Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.Mol.Cell Biol.20, 4106-4114 (2000).
51. Wen, P.J.et al.Phosphatidylinositol(4,5)bisphosphate coordinates actinmediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells.Nat.Commun.2, 491 (2011).
52. Saura, J., Tusell, J.M.& Serratosa, J.High-yield isolation of murine microglia by mild trypsinization.Glia 44, 183-189 (2003).